Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by NISHIZAWA, T.
Right arrow Articles by AKAOKA, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NISHIZAWA, T.
Right arrow Articles by AKAOKA, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1978 British Society for Rheumatology

research-article

TREATMENT OF GOUT WITH ALTERNATE-DAY HYPO-URICAEMIC DRUGS

TSUNEO NISHIZAWA1,, YUTARO NISHIDA2, TAKEHIRO MASUDA2 and IEO AKAOKA2

1Division of Rheumatology and Allergy, Department of Medicine Japanese Red Cross Medical Center 4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
2Department of Medicine and Physical Therapy, Faculty of Medicine, University of Tokyo 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan

Correspondence to: Requests for reprints to Dr. T. Nishizawa

In the treatment of gout, an alternate-day hypo-uricaemic drug was tried in order to reduce the amount of hypo-uricaemic drug prescribed and to lessen its possible side-effects. The serum urate level in the alternate-day therapy with benzbromarone (100 mg/day) was higher than that found with daily therapy, but was conversely lower than that in half-dose daily therapy. The serum urate level in alternate-day therapy with five hypo-uricaemic drugs increased by 0.7 mg to 1.4 mg/100 ml, compared with that in the daily therapy. The incidence of hyperuricaemia (serum uric acid over 7 mg/100 ml) in alternate-day therapy with a long-acting hypo-uricaemic drug was relatively low (0 % for bucolome, 20 % for probenecid and 25.0 % for benzbromarone). The incidence of hyperuricaemia in alternate-day therapy with sulphinpyrazone and allopurinol was 42.9 % and 66.7 %, respectively. The frequency of gouty attacks in alternate-day therapy with five drugs was not significantly different, when compared with daily therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.